The screening results identified numerous new actions, which we confirmed by docking for CB2, H1/3/4, and D3 receptors, potentially addressing unmet medical needs in neuroinflammation, obesity, allergic dermatitis, and CNS disorders. The gene discussed is CNR2; the disease is atopic eczema.